LIPAC Oncology announces successful completion of phase 1 bladder cancer clinical study and initiation of phase 2A study

This article was originally published here

Phase 1 study results showed escalating doses of TBC-1002 to be well tolerated with no dose limiting toxicity and no irritative voiding (cystitis) symptoms. No systemic exposure or

The post LIPAC Oncology announces successful completion of phase 1 bladder cancer clinical study and initiation of phase 2A study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply